FDA's position on the clozaril patient management system.
C C
CC
Peck
D000380:Agranulocytosis / Q000139:chemically induced*; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D003984:Dibenzazepines / Q000009:adverse effects*; D004348:Drug Labeling / Q000331:legislation & jurisprudence*; D006801:Humans; D007958:Leukocyte Count / Q000379:methods; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
D003984:Dibenzazepines; D003024:Clozapine